Share This Page
Drugs in ATC Class A10B
✉ Email this page to a colleague
Subclasses in ATC: A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Market dynamics and patent landscape for ATC class A10B (blood glucose–lowering drugs, excl. insulins)
ATC A10B market expansion is driven by GLP-1 and GIP/GLP-1 agonists, SGLT2 inhibitors, and DPP-4 inhibitors, with exclusivity and patent cliffs increasingly segmented by molecule-level primary patents plus formulation, device-adjacent, and method-of-use filings. Patent risk concentrates in three zones: (1) early-2020s “reformulation” and line-extension IP around oral fixed-dose combinations and incretin dose escalations; (2) SGLT2 composition and polymorph/manufacturing patents extending through the mid-to-late 2020s; and (3) GLP-1 peptide and acylation/lipid conjugate families where combination products and new indications drive ongoing patent thickets. Legal challenges are moving from “Paragraph IV generic” to broader, sometimes design-around-centric disputes that target process and salt/form differences, and to biosimilar-style challenges for complex peptides where applicable.
Scope note for this patent analysis: ATC A10B excludes insulins. The largest patent-relevant ecosystems within A10B are GLP-1 receptor agonists (and dual incretins), SGLT2 inhibitors, and DPP-4 inhibitors; the competitive set also includes sulfonylureas, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, and older agents, each with different patent aging and regulatory generics prevalence.
How are ATC A10B blood glucose–lowering drugs performing and what markets are driving growth?
Which A10B drug classes dominate revenues and growth
The market is concentrated in incretin-based therapies and SGLT2 inhibitors. DPP-4 inhibitors have a mature generic footprint in many geographies, while sulfonylureas and older oral agents have high generic penetration and limited residual innovation-led patent estates outside specific combinations and novel dosing regimens.
Growth drivers that affect patent strategy:
- Chronicity and adherence engineering: once-weekly and oral formats shift IP toward peptide chemistry, long-acting formulations, stability, and delivery performance.
- Dose and label expansion: new CV outcome populations, renal outcome claims, and combination positioning increase the value of method-of-use patents and clinical-data-dependent compositions.
- Combination portfolio build-out: fixed-dose combinations (FDCs) create layered estates: each component’s molecule patents plus combination and specific dosing-form patents.
Where payer and guideline dynamics shift competitive intensity
- Preferential formularies for incretins and SGLT2 inhibitors concentrate near-term volume and reduce generic substitution willingness while patents remain in force.
- Net price pressure accelerates as patents near expiration in each molecule. This increases incentives to launch “at-risk” products and to challenge secondary patents that block entry.
Actionable implication for patent-landscape work: the most economically material patents are often the “secondary” ones tied to formulation, stability, device, and use in newer populations, because those are the ones that can delay early generic or biosimilar competition even after primary substance claims expire.
What patents protect A10B molecules and how is the IP layered?
Typical patent stack in A10B (high level)
Most commercially relevant molecules in A10B have a layered estate that can include:
- Core composition-of-matter (active ingredient, salts, polymorphs, specific stereochemistry)
- Process and intermediate claims (how the compound is made)
- Formulation and device-linked claims (long-acting injectables, oral dosage performance)
- Method-of-use claims (specific patient subsets, endpoints, dosing regimens, combinations)
- Combination patents (FDC fixed-dose ratios and dosing schedules)
- Manufacturing method and stability patents (particularly important for peptides and extended-release oral systems)
How do long-acting peptides reshape the patent landscape
For GLP-1 and dual agonists, the IP center of gravity often shifts to:
- Peptide modification chemistry (acylation or linker strategies)
- Long-acting formulation platform (suspension stability, depot formation control, injection tolerability)
- Device-related parameters that constrain generic design choices
How do SGLT2 inhibitors extend exclusivity
SGLT2 inhibitors commonly retain protection through:
- Specific salt/polymorph forms
- Crystallization and manufacturing process claims
- Tablet formulations and dissolution profiles
- Use in specific renal or CV outcome populations
DPP-4 inhibitors: what remains patent-relevant
DPP-4 inhibitors frequently have:
- Primary patents largely expired or late-stage
- **Residual IP concentrated in:
- improved combinations
- fixed-dose pairings
- line extension formulations
- specific dosing in subpopulations where method-of-use claims survive
When does exclusivity end for ATC A10B drugs and what timelines matter for generic entry?
Answer: the market “clock” is multi-variable
Exclusivity and patent clocks differ by:
- Patent expiration (utility and potentially PTE adjusted)
- Regulatory exclusivity (data exclusivity, where applicable)
- Orphan or pediatric exclusivity (if claimed)
- Orange Book “listed” patents that determine FDA approval pathway bottlenecks
- Remaining method-of-use and formulation patents that can be enforced even when base composition patents end
Common timeline patterns by class
GLP-1 / dual incretin injectables:
- Substance and long-acting chemistry patents tend to run near primary expiry
- Secondary patents on formulation and specific dosing populations can delay generic entry materially
- “New indication” method-of-use claims can remain enforceable if they are listed and not invalidated
SGLT2 inhibitors (oral):
- Often longer tail via process, polymorph, and formulation
- Generic approval may be delayed if Orange Book-listed formulation or method-of-use patents are not cleared
DPP-4 inhibitors:
- Lower “moving target” risk in many markets because estates are typically mature
- Most remaining obstacles are around combinations and line extensions
What is the Orange Book status of A10B blood glucose–lowering drugs and which patents block generics?
Orange Book entry logic for A10B
FDA’s Orange Book lists patents tied to:
- Active ingredient
- Approved formulation
- Method of use claims
For generic entry, the critical factor is whether the ANDA applicant files:
- Paragraph IV certifications against listed patents, or
- Carves out around method-of-use patents, or
- Seeks approval after expiration/waiver of listed patents.
Where the bottlenecks concentrate
Across A10B classes, the patents most likely to block generic entry are:
- Formulation patents for controlled-release or long-acting injectables
- Method-of-use claims tied to CV and renal outcomes
- Combination patents for FDC products
Actionable implication: the “listed” patent set defines the procedural entry path and settlement leverage, not the full estate.
How strong is the patent estate for A10B molecules: what patents hold up in litigation?
Key strength indicators
Patent enforcement outcomes in A10B tend to correlate with:
- Claim breadth that captures common design-around variants
- Support in specification that withstands enablement and written description challenges
- Whether the asserted patent is truly “listed” and therefore procedurally tied to FDA approval
- Whether the claimed invention is formulation or method-of-use (these can be harder to “avoid” if the generic must match exposure and clinical endpoints)
Validity and infringement attack patterns
Common defenses and counter-attacks include:
- Anticipation and obviousness from prior art peptides/compounds or generic formulation disclosure
- Non-infringement via salt/polymorph differences and process changes
- Indefiniteness and inadequate disclosure for complex formulation parameters
- Lack of patentability for incremental line extensions that may be framed as obvious improvements
Which companies are challenging A10B patents and how do Paragraph IV cases shape the market?
Answer: challenge activity is concentrated among major generic and specialty players
In A10B, Paragraph IV activity is primarily driven by:
- Large US generic companies (multiple ANDAs with portfolio-level filing strategy)
- Specialty and biosimilar-adjacent developers for complex peptide formats where applicable
- Indian and other API/formulation suppliers feeding generic manufacturing ecosystems
Market impact of challenges:
- Settlements often trade off “early launch” dates against ongoing royalty/licensing or delayed exclusivity outcomes.
- Where a settlement is reached, it can anchor the competitive timeline and shape payer expectations.
What patent litigation affects A10B drugs and what are the typical settlement structures?
Litigation impact channels
- Injunction pressure: delay of FDA approval and launch until patent expiry or settlement
- At-risk launch leverage: if the court pace exceeds expected decision windows
- Design-around constraints: even after a partial victory, device/formulation performance constraints can delay entry
Typical settlement archetypes in A10B
- “Delayed launch” agreements: generic agrees to launch after a defined date for some or all products
- Royalty-based settlements: generic pays a royalty for a period
- Portfolio-specific carve-outs: settlements may apply only to certain strengths, formulations, or indications
- Adjudicated non-infringement outcomes that allow faster entry but constrain later line extensions
How do formulation patents for A10B affect generics even when APIs are off-patent?
Formulation and manufacturing constraints are pivotal
For many A10B products, generic entry can be blocked not by the molecule, but by:
- Long-acting depot characteristics that affect release kinetics
- Stability and degradation profiles
- Excipients and concentration-dependent performance parameters
- Polymorph-specific or crystallization-controlled API forms
Design-around realities
Even if a generic can match label claims pharmaceutically, Orange Book-listed formulation patents can still prevent approval unless:
- the patent is expired,
- cleared via court decisions,
- or carved out through certification strategies.
What generic entry risks exist for A10B: what products are most exposed near patent cliffs?
Answer: exposure concentrates where (a) primary patents are near expiry, and (b) secondary patents are narrower
High risk tends to occur when:
- The molecule’s primary composition claims expire earlier than long-acting formulation or method-of-use claims
- Litigation history suggests claim invalidation risk
- Generic developers have credible non-infringement pathways (e.g., different polymorphs, different release profiles)
Lower risk tends to occur when
- Asserted patents remain broad and enforceable in court
- Orange Book-listed method-of-use claims are tightly linked to clinical trial datasets and label outcomes
- Long-acting formulation patents are difficult to design around without changing product characteristics
How does ATC A10B compare across major drug classes on patent maturity and competition?
Comparative patent maturity matrix
| A10B class | Patent maturity (US/EU typical) | Primary competitive risk | Typical “hard” IP to clear |
|---|---|---|---|
| GLP-1 RA and dual incretins | Mid-to-late (active filings and line extensions) | Delayed generic entry via formulation and method-of-use | Long-acting chemistry and formulation; CV/renal method-of-use |
| SGLT2 inhibitors | Mid (ongoing extensions) | Process/formulation-driven blocking | Polymorph/crystal and manufacturing; formulation dissolution specs; outcome use patents |
| DPP-4 inhibitors | Mature (more generic adoption) | Combination/FDC and line extension | Combination patents and specific dosing regimens |
| Sulfonylureas/meglitinides | Mature | Lower litigation intensity | Mostly combination/formulation, limited new use claims |
| Thiazolidinediones/alpha-glucosidase inhibitors | Mature | Minimal innovation-led patent blocks | Rarely a major bottleneck unless newer combos exist |
Where are A10B patent cliffs likely: what years matter for business planning?
Answer: plan by molecule-specific expiry and listed-patent status, not by class
For business planning, the operative year is when the last relevant Orange Book-listed patent (or enforceable adjusted expiry) ends for each product strength and dosage form. In practice:
- Injectables and long-acting forms often have later cliff dates than immediate-release tablets due to formulation and device-linked patents.
- Combination products typically have later cliffs because they require clearing multiple patent layers.
Commercial planning implication: track each marketed NDC separately, because strength and dosage-form can have different listed patents, expiry calendars, and settlement obligations.
What manufacturing and IP barriers block generic or biosimilar competition in A10B?
Key barriers
- API polymorph and manufacturing process dependence (especially for oral SGLT2 inhibitors)
- Peptide synthesis and long-acting formulation reproduction (for GLP-1 therapies)
- Supply chain IP tied to control of critical quality attributes
- Device and administration system constraints for injectables
These barriers can drive settlement leverage because even an authorized FDA approval path can fail if the product cannot satisfy formulation performance obligations tied to clinical acceptance and labeling.
Key takeaways
- A10B’s patent landscape is dominated by incremental layering around formulation, process, and method-of-use rather than only active ingredient composition claims.
- Exclusivity and Orange Book-listed patents define the practical generic entry window; secondary patents frequently drive delay.
- Litigation and settlements are moving toward design-around and formulation/process leverage, making listed patent clearance the central planning variable.
- Competitive exposure is molecule- and NDC-specific, with long-acting injectables and fixed-dose combinations showing the most complex residual IP blocks.
FAQs
- Which A10B drug classes have the most Orange Book-listed formulation patents delaying ANDA approval?
- How do method-of-use patents tied to CV or renal outcomes affect generic “carve-out” strategies for A10B drugs?
- What role do polymorph and crystallization patents play in SGLT2 inhibitor generic entry timing?
- How do settlement dates in A10B Paragraph IV disputes translate into launch risk for at-risk generics?
- Which A10B product formats (oral tablets vs long-acting injectables vs fixed-dose combinations) create the highest manufacturing/IP barriers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Guidance for Industry: Patent Certifications and Eligibility for Approval Under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration.
- European Patent Office. General information on supplementary protection certificates (SPC) and patent term adjustments. European Patent Office.
More… ↓
